14/12/2020: Clinical study that meets French National Authority for Health requirements highlights the quality of the tests marketed by Theradiag

Croissy-Beaubourg, December 14, 2020 – 8.00 am CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, announces the publication of a study that meets French National Authority for…

Continue Reading 14/12/2020: Clinical study that meets French National Authority for Health requirements highlights the quality of the tests marketed by Theradiag

08/12/2020: Theradiag obtains €1.9 million of non-dilutive financing in the form of a state-guaranteed loan

Croissy-Beaubourg, December 8, 2020 – 5:45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained a €1.9 million state-guaranteed loan (Prêt Garanti…

Continue Reading 08/12/2020: Theradiag obtains €1.9 million of non-dilutive financing in the form of a state-guaranteed loan